MetaCap

Anbio Biotechnology (NNNN) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Teknova (TKNO) has outperformed Anbio Biotechnology (NNNN) over the past year, gaining 77.4% versus a loss of 86.0%. Alpha Teknova is the larger company by market cap ($480.0 million vs $145.7 million), about 3.3 times the size. Anbio Biotechnology converts more of its revenue into profit, with a net margin of 74.1% versus -42.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NNNN-86.02%TKNO+77.44%
+127%+15%-97%
Nov 21, 20251 yearNov 20, 2026
NNNN-42.46%TKNO+2.42%
+828%+356%-116%
Feb 17, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NNNN versus TKNO key metrics
MetricNNNNTKNO
Share price$3.32$7.63
Market cap$145.72M$479.95M
1-day change-9.04%-2.30%
YTD return-88.96%+100.79%
1-year return-86.02%+77.44%
5-year return—-63.63%
P/E ratio (TTM)22.13—
EPS (TTM)$0.15$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$8.65M$40.52M
Revenue growth (YoY)+5.64%+7.35%
Net income (latest FY)$6.40M$-17.26M
Gross margin87.24%33.17%
Operating margin66.70%-41.90%
Net margin74.06%-42.59%
52-week high$44.73$9.48
52-week low$3.09$1.91
Distance from 52-week high-92.58%-19.51%
Analyst consensus—none
Avg. price target upside—+28.83%
Average volume128.35K437.31K
Shares outstanding43.89M62.90M
Employees27158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Alpha Teknova is about 3.3 times larger than Anbio Biotechnology by market value ($479.95M vs $145.72M).
  • TKNO has outperformed NNNN by 163.5 percentage points over the past year.
  • Anbio Biotechnology is more profitable, keeping 74.1 cents of every revenue dollar as net income versus -42.6 cents for Alpha Teknova.

About Anbio Biotechnology

NNNN stock →

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

NNNN vs TKNO FAQ

Which is bigger, Anbio Biotechnology or Alpha Teknova?

Alpha Teknova (TKNO) is larger, with a market capitalization of $479.95M compared with $145.72M for Anbio Biotechnology (NNNN).

Which stock has performed better over the past year, NNNN or TKNO?

TKNO returned +77.44% over the past 12 months, compared with -86.02% for NNNN (price return, excluding dividends). Past performance does not predict future results.

Are Anbio Biotechnology and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons